Parvin K Aminolroaya Law

About Parvin K Aminolroaya Law

Parvin is an emerging leader within the Plaintiffs’ bar where she represents plaintiffs in mass tort and class action cases. She litigates product liability and class action cases and prepares them for trial. Parvin was appointed co-lead counsel in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, consolidating dozens of lawsuits against drugmakers Novo Nordisk and Eli Lilly filed by patients who took Ozempic and other similar GLP-1 RA medications and suffered serious injuries. Parvin serves as co-lead counsel in the Elmiron Products Liability litigation, a nationwide multi-district litigation against numerous pharmaceutical companies, including Janssen, alleging that the companies failed to tell doctors and patients about the risk of permanent vision injury with the drug Elmiron. In the Testosterone Replacement Therapy Products Liability Litigation, where it was alleged that Androgel caused heart attacks and strokes in users, she worked on multiple bellwether trial teams and was responsible for presenting a key FDA regulatory expert in a trial that resulted in an initial verdict of $140 million for the plaintiff. A series of bellwether trials in that litigation resulted in more than $290 million in initial verdicts. Parvin also worked on the 3M Earplug litigation in which it was alleged that 3M knowingly marketed, manufactured, and sold dangerously defective earplugs. She prepared expert and fact witnesses for a bellwether trial that resulted in a $110M verdict against 3M. In addition to her trial work, Parvin also often leads the development of regulatory and scientific experts in pharmaceutical drug and device cases. In Elmiron, she led the development of multiple causation and liability experts. She has also co-led teams handling a key FDA expert for the nationwide Opioids MDL litigation and the Hernia Mesh MDL litigation.